Proton Pump Inhibitor Prescriptions and Subsequent Use in US Veterans Diagnosed with Gastroesophageal Reflux Disease

被引:23
|
作者
Gawron, Andrew J. [1 ,2 ,3 ]
Pandolfino, John E. [1 ]
Miskevics, Scott [3 ]
LaVela, Sherri L. [2 ,3 ]
机构
[1] Northwestern Univ, Feinberg Sch Med, Div Gastroenterol & Hepatol, Chicago, IL 60613 USA
[2] Northwestern Univ, Feinberg Sch Med, Ctr Healthcare Studies, Chicago, IL 60613 USA
[3] Edward Hines Jr VA Hosp, Dept Vet Affairs, Ctr Management Complex Chron Care, Hines, IL USA
基金
美国医疗保健研究与质量局;
关键词
drug; GERD; prescriptions; Veteran Health Affairs; RISK; ADHERENCE; THERAPY; MEDICATION; MAGNITUDE; FRACTURE; OVERUSE; IMPACT;
D O I
10.1007/s11606-013-2345-0
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Empiric proton pump inhibitor use is common for gastroesophageal reflux disease (GERD), but initial proton pump inhibitor (PPI) prescription patterns in Veterans are unknown. The study aims were to determine initial PPI prescriptions in Veterans diagnosed with GERD, and to characterize subsequent PPI use over the 2 years following initial prescription. We conducted a retrospective study using Veteran's Administration (VA) administrative data and chart review. Patients diagnosed with GERD and provided an initial PPI prescription at Hines VA Hospital from 2003 to 2007, with 2 year follow-up for each patient (through 2009). Initial PPI prescriptions were categorized as standard total daily dose or high total daily dose, and accuracy was confirmed by manual chart review. Descriptive statistics were calculated and bivariate analyses were used to assess for differences in demographics, prescriptions, and subsequent use by initial PPI dosage category. Of the 1,621 patients included in the study, 378 (23.3 %) had high total daily dose initial PPI prescriptions and 1,243 (76.7 %) patients had standard total daily dose initial prescriptions. The majority of patients (65.8 %) received a 90-day or greater initial prescription. Over the 2 years following the initial PPI prescription, 13.0 % of patients with initial standard daily dose prescriptions had evidence of step-up therapy. Only 7.1 % of patients with initial high daily dose PPI prescriptions had evidence of step-down therapy. A large majority of patients (83.8 %) had at least one refill over 2 years, and the overall medication possession ratio was 0.86. Many Veterans receive high total daily dose PPI prescriptions as initial therapy for a GERD diagnosis, and few patients have evidence for cessation or reduction of therapy. These results provide detailed data on prescribing and use of PPIs to help guide efforts for optimal PPI use in US Veterans.
引用
收藏
页码:930 / 937
页数:8
相关论文
共 50 条
  • [31] Prevalence of bile reflux in gastroesophageal reflux disease patients not responsive to proton pump inhibitors
    Monaco, Luigi
    Brillantino, Antonio
    Torelli, Francesco
    Schettino, Michele
    Izzo, Giuseppe
    Cosenza, Angelo
    Di Martino, Natale
    WORLD JOURNAL OF GASTROENTEROLOGY, 2009, 15 (03) : 334 - 338
  • [32] Proton Pump Inhibitor Use in the US Ambulatory Setting, 2002-2009
    Rotman, Stephen R.
    Bishop, Tara F.
    PLOS ONE, 2013, 8 (02):
  • [33] Evaluation of efficacy of proton pump inihibitors in refractory gastroesophageal reflux disease
    Kim, Eun Hye
    Lee, Donghwan
    Park, Kyungsoo
    Chung, Hyunsoo
    Lee, Hyuk
    Park, Jun Chul
    Shin, Sung Kwan
    Lee, Sang Kil
    Chung, Jae Bock
    Lee, Yong Chan
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 : 290 - 290
  • [34] Positive predictors for gastroesophageal reflux disease and the therapeutic response to proton- pump inhibitors
    Becker, Valentin
    Grotz, Stefan
    Schlag, Christoph
    Nennstiel, Simon
    Beitz, Analena
    Haller, Bernhard
    Schmid, Roland M.
    Meining, Alexander
    Bajbouj, Monther
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (14) : 4017 - 4024
  • [35] Value of the Gastroesophageal Reflux Disease Questionnaire (GerdQ) in predicting the proton pump inhibitor response in coronary artery disease patients with gastroesophageal reflux-related chest pain
    He, S.
    Liu, Y.
    Chen, Y.
    Tang, Y.
    Xu, J.
    Tang, C.
    DISEASES OF THE ESOPHAGUS, 2016, 29 (04) : 367 - 376
  • [36] Do patients with gastroesophageal reflux disease exhibit compromised bone quality prior to proton pump inhibitor therapy?
    Aasarod, Kristin M.
    Mosti, Mats P.
    Finstad, Malin T.
    Stunes, Astrid K.
    Fossmark, Reidar
    Syversen, Unni
    BONE REPORTS, 2021, 14
  • [37] Prevalence and predictors of proton pump inhibitor partial response in gastroesophageal reflux disease in systemic sclerosis: a prospective study
    Foocharoen, Chingching
    Chunlertrith, Kitti
    Mairiang, Pisaln
    Mahakkanukrauh, Ajanee
    Suwannaroj, Siraphop
    Namvijit, Suwassa
    Wantha, Orathai
    Nanagara, Ratanavadee
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [38] What is the place of empirical proton pump inhibitor testing in the diagnosis of gastroesophageal reflux disease? (Description, duration, and dosage)
    Vardar, Rukiye
    Keskin, Muharrem
    TURKISH JOURNAL OF GASTROENTEROLOGY, 2017, 28 : S12 - S15
  • [39] Gastro-Oesophageal Reflux Disease Beyond Proton Pump Inhibitor Therapy
    Hershcovici, Tiberiu
    Fass, Ronnie
    DRUGS, 2011, 71 (18) : 2381 - 2389
  • [40] Inconsistency in the Diagnosis of Functional Heartburn: Usefulness of Prolonged Wireless pH Monitoring in Patients With Proton Pump Inhibitor Refractory Gastroesophageal Reflux Disease
    Penagini, Roberto
    Sweis, Rami
    Mauro, Aurelio
    Domingues, Gerson
    Vales, Andres
    Sifrim, Daniel
    JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY, 2015, 21 (02) : 265 - 272